BioLife Solutions Inc (NASDAQ:BLFS) issued its quarterly earnings results on Thursday. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by $0.02. BioLife Solutions had a negative net margin of 59.91% and a negative return on equity of 57.51%. The business had revenue of $2.37 million during the quarter, compared to analyst estimates of $2.10 million.
Shares of BioLife Solutions (NASDAQ:BLFS) traded up 3.4484% during trading on Friday, reaching $2.3069. The company’s stock had a trading volume of 86,417 shares. The stock’s 50 day moving average price is $2.06 and its 200-day moving average price is $1.84. BioLife Solutions has a 52-week low of $1.43 and a 52-week high of $3.58. The stock’s market cap is $29.99 million.
Separately, Maxim Group initiated coverage on BioLife Solutions in a research note on Thursday, January 19th. They issued a “buy” rating and a $3.00 price target on the stock.
About BioLife Solutions
BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.